



Article scientifique

Article

2017

Published version

Open Access

This is the published version of the publication, made available in accordance with the publisher's policy.

---

## GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study

---

Ansari Djaberi, Marc Georges; Curtis, Patricia; Uppugunduri Satyanarayana, Chakradhara Rao; Rezgui, Mohammed Aziz; Nava, Tiago; Mlakar, Vid; Lesne, Laurence; Théoret, Yves; Chalandon, Yves; Dupuis, Lee L; Schechter, Tao; Bartelink, Imke H; Boelens, Jaap J; Bredius, & Robbert [and 8 more]

### How to cite

ANSARI DJABERI, Marc Georges et al. GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. In: *Oncotarget*, 2017, vol. 8, n° 53, p. 90852–90867. doi: 10.18632/oncotarget.20310

This publication URL: <https://archive-ouverte.unige.ch/unige:107417>

Publication DOI: [10.18632/oncotarget.20310](https://doi.org/10.18632/oncotarget.20310)

## GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study

Marc Ansari<sup>1,2</sup>, Patricia Huezo-Diaz Curtis<sup>1,2,\*</sup>, Chakradhara Rao S. Uppugunduri<sup>1,2,\*</sup>, Mohammed Aziz Rezgui<sup>3</sup>, Tiago Nava<sup>1,3,5,6</sup>, Vid Mlakar<sup>1,2</sup>, Laurence Lesne<sup>1,2</sup>, Yves Théoret<sup>3,4,5</sup>, Yves Chalandon<sup>7</sup>, Lee L. Dupuis<sup>8</sup>, Tao Schechter<sup>8</sup>, Imke H. Bartelink<sup>9,17</sup>, Jaap J. Boelens<sup>9</sup>, Robbert Bredius<sup>10</sup>, Jean-Hugues Dalle<sup>11</sup>, Saba Azarnoush<sup>11</sup>, Petr Sedlacek<sup>12</sup>, Victor Lewis<sup>13</sup>, Martin Champagne<sup>14</sup>, Christina Peters<sup>15</sup>, Henrique Bittencourt<sup>3,4,5,16</sup> and Maja Krajinovic<sup>3,4,5,16,18</sup>

<sup>1</sup> Department of Pediatrics, CANSEARCH Research Laboratory, Faculty of Medicine, Geneva, Switzerland

<sup>2</sup> Department of Pediatrics, Onco-Hematology Unit, Geneva University Hospital, Geneva, Switzerland

<sup>3</sup> Charles-Bruneau Cancer Center, CHU Sainte-Justine Research Center, Montreal, Quebec, Canada

<sup>4</sup> Department of Pharmacology, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada

<sup>5</sup> Clinical Pharmacology Unit, CHU Sainte-Justine, Montreal, Quebec, Canada

<sup>6</sup> Faculty of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

<sup>7</sup> Department of Medical Specialties, Division of Hematology, Geneva University Hospital, Geneva, Switzerland

<sup>8</sup> Department of Haematology/Oncology, Blood and Marrow Transplant Unit, The Hospital for Sick Children, Toronto, Ontario, Canada

<sup>9</sup> Pediatric Blood and Marrow Transplantation Program, University Medical Center, Utrecht, The Netherlands

<sup>10</sup> Department of Pediatrics, Center of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands

<sup>11</sup> Pediatric Hematology Department, Robert Debré Hospital, Assistance Publique, Hôpitaux de Paris, Paris, France

<sup>12</sup> Department of Pediatric Hematology and Oncology Teaching Hospital, 2nd Medical School, Charles University, Prague, Czech Republic

<sup>13</sup> Department of Pediatrics, Alberta Children's Hospital, Calgary, Alberta, Canada

<sup>14</sup> Department of Hematology, Hospital Verdun, Montreal, Quebec, Canada

<sup>15</sup> Department of Pediatrics, Stem Cell Transplantation Unit, St Anna Children's Hospital, Vienna, Austria

<sup>16</sup> Department of Pediatrics, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada

<sup>17</sup> Department of Medicine, The University of California San Francisco, San Francisco, CA, USA

<sup>18</sup> On Behalf of the Pediatric Disease Working Party of the European Society for Blood and Marrow Transplantation, Leiden, The Netherlands

\* These authors have contributed equally to this work

**Correspondence to:** Patricia Huezo-Diaz Curtis, **email:** Patricia.Curtis@unige.ch

**Keywords:** busulfan, pharmacokinetics, pharmacogenetics, toxicity, hematopoietic stem cell transplantation

**Received:** July 18, 2017

**Accepted:** July 23, 2017

**Published:** August 27, 2017

Copyright: Ansari et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### ABSTRACT

**Busulfan (BU) dose adjustment following therapeutic drug monitoring contributes to better outcome of hematopoietic stem cell transplantation (HSCT). Further improvement could be achieved through genotype-guided BU dose adjustments. To investigate this aspect, polymorphism within glutathione S transferase genes were assessed. Particularly, promoter haplotypes of the glutathione S transferase A1 (GSTA1) were evaluated *in vitro*, with reporter gene assays and clinically, in a pediatric multi-center study (N =138) through association with BU pharmacokinetics (PK) and clinical outcomes. Promoter activity significantly differed between the GSTA1**

**haplotypes ( $p < 0.001$ ) supporting their importance in capturing PK variability. Four *GSTA1* diplotype groups that significantly correlated with clearance ( $p = 0.009$ ) were distinguished. Diplotypes underlying fast and slow metabolizing capacity showed higher and lower BU clearance (ml/min/kg), respectively. *GSTA1* diplotypes with slow metabolizing capacity were associated with higher incidence of sinusoidal obstruction syndrome, acute graft versus host disease and combined treatment-related toxicity ( $p < 0.0005$ ). Among other *GST* genes investigated, *GSTP1 313GG* correlated with acute graft versus host disease grade 1-4 ( $p = 0.01$ ) and *GSTM1 non-null* genotype was associated with hemorrhagic cystitis ( $p = 0.003$ ). This study further strengthens the hypothesis that *GST* diplotypes/genotypes could be incorporated into already existing population pharmacokinetic models for improving first BU dose prediction and HSCT outcomes. (N° Clinicaltrials.gov identifier: NCT01257854. Registered 8 December 2010, retrospectively registered).**

## INTRODUCTION

Myeloablative conditioning regimens comprising the bi-functional alkylating agent busulfan (BU) were introduced in the late 1970s as an alternative to total body irradiation [1]. Since then BU has been extensively used, especially in combination with cyclophosphamide in patients undergoing hematopoietic stem cell transplantation (HSCT) [2]. Studies in children and adults demonstrate reduced toxicity and increased efficacy, when the BU area under the curve concentration (AUC) is within optimal target range [3, 4]. Hence, dose adjustment guided by therapeutic drug monitoring is performed to prevent treatment-related toxicities. In a recent study comparing the performance of 12 pediatric dosing guidelines, the therapeutic target window can be reached in approximately 51% to 74% in pediatric cases and 45% to 64% in infants [5]. Nevertheless, the authors and others also caution about emerging evidence that the therapeutic AUC range of 3.7 - 6.2 mg.h/L per dose (equivalent ~ steady state concentration,  $C_{ss}$ , of 615 - 1031.3 ng/mL) should not be universally applied as the optimal AUC may depend on the indication for transplant or other patient-related factors [5-8]. Recently, a narrower optimal i.v. BU cumulative AUC of 78-101 mg.h/L (equivalent to a  $C_{ss}$  of ~ 830-1050 ng/mL) has been suggested to improve outcomes irrespective of disease condition, based on the analysis of 674 pediatric patients [4]. This proposed narrower therapeutic window constitutes a need to identify the underlying factors responsible for the inter-individual variability of BU clearance (CL), particularly at first dose before BU adjustment.

BU is eliminated via conjugation with glutathione catalyzed by glutathione S-transferase enzymes (GST) especially by the Glutathione S Transferase Alpha1 (*GSTA1*) isoform followed, to a lesser extent, by the Glutathione S Transferase Mu 1 (*GSTM1*) and Glutathione S Transferase Pi 1 (*GSTP1*) [9]. Factors that could affect the metabolism or elimination of BU are the availability of glutathione, efflux of conjugates by transporter proteins Unmarked set by huezodia and the different activity of GSTs [2, 10]. The GSTs are highly

polymorphic; the promoter region of *GSTA1* contains polymorphic variants that influence enzyme function [3, 11, 12]. A null variant is encountered for *GSTM1*, whereby the entire gene is deleted in a considerable proportion of different populations, resulting in the complete absence of the corresponding enzyme activity [13]. *GSTP1* contains the 313A>G polymorphism leading to an Ile-to-Val substitution that has shown to decrease enzyme activity [14]. Our team and other groups have investigated genetic variants in *GSTs* for their association with BU exposure and/or clinical outcomes [15-33], summarized in Supplementary Table 1. Most studies demonstrated an association between BU pharmacokinetics (PK) and *GSTA1*-69 C>T, [15-28] which delineates haplotypes \*A and \*B. Nevertheless, functional assessment of *GSTA1* sub-haplotypes and more detailed insight into their relationship with clinical outcomes in a larger patient population is still lacking. In this report, we analyzed promoter activity of each *GSTA1* haplotype subgroup and have extended our previous analysis of pediatric patients from a single center [20] to a larger multicenter cohort to validate the association of *GST* genes, particularly *GSTA1* haplotype combinations as diplotypes, with BU exposure and clinical outcomes of HSCT.

## RESULTS

### Functional characterization of the *GSTA1* polymorphisms

To explore how *GSTA1* function is related to each *GSTA1* haplotype (Figure 1a), we estimated promoter activity by luciferase gene reporter using six haplotype constructs that were transiently transfected in human hepatoma (HEPG2) cells. Results are illustrated in Figure 1b, where a significant increase of luciferase activity was observed when \*A1 was mutated at position -631 forming \*A2 and at position -1142 forming \*A3 haplotype ( $p < 0.001$ ). In contrast, the promoter activity was significantly decreased in the case of all \*B haplotypes that are


conjunctly delineated from haplotype *\*A* by changes at three positions in full linkage disequilibrium (-52, -69, -567). The lowest activity among *\*B* haplotypes was observed for *\*B1b* (defined by position -513,  $p = 0.00001$ ) that equalled the activity of the promoterless plasmid.

### Pharmacogenetics vs pharmacokinetics and dose requirement

Based on the functional effect of each haplotype, predicted activity of each diplotype and the relationship with CL (ml.min/kg), four major functional *GSTA1* groups were revealed Table 1; I (in 9.4% cases), defined by two copies of rapid metabolizing alleles, mostly represented by

*\*A2\* A2* individuals, *group IV* (14.5%) represented by two copies of slow metabolizing alleles (defined in all cases but one by *\*B1a\* B1a* diplotype) and by the presence of one copy of very slow metabolizing *\*B1b* allele. *Group II* (28.2%) and *III* (47.8%) had intermediate to normal metabolizing capacity and were defined by the presence of *\*A2* and *\*A1*, respectively. Linear effect was observed, whereby *group I* demonstrated highest and *group IV* lowest CL ( $p = 0.009$ , Figure 2a) with even more evident correlation seen in girls ( $p \leq 0.0005$ , Figure 2b).

Due to the difference in dose adjustment across participating centers, the ratio of adjusted to initial dose and cumulative AUC obtained in a single center (University Hospital Center Sainte Justine, Montreal) was compared among *GSTA1* diplotype groups. Patients



**Figure 1: *GSTA1* Haplotype and Reporter Gene assay of *GSTA1* promoter.** A. Haplotypes investigated with luciferase reporter assay. rs (reference SNP ID) numbers correspond to each SNP included for site directed mutagenesis. SNPs used for genotyping and for inferring sub-haplotypes in patients are highlighted in bold. B. Luciferase activities of the proximal promoters of *GSTA1* variants (*GSTA1\* A1*, *GSTA1\* A2*, *GSTA1\* A3*, *GSTA1\* B1a*, *GSTA1\* B2*, *GSTA1\* B1b*) in transient transfection in HepG2 cells. Error bars represent the standard deviations. Pairwise comparisons by analysis of variance (ANOVA) between data for the *GSTA1\* A1* vs. any other haplotype, after Bonferroni correction \*\*\* =  $p < 0.001$ ; \*\*\*\* =  $p < 0.0001$ , \*\*\*\*\* =  $p < 0.000001$ .

**Table 1: *GSTA1* diplotype frequencies in the study population and proposed functional groups**


<i>GSTA1</i> Diplotype	Diplotype Frequencies		Proposed Functional group
	N (%)		
<i>GSTA1</i> *A2*A2	12 (8.7)		I (9.4%)
<i>GSTA1</i> *A2*A3	1 (0.7)		
<i>GSTA1</i> *A2*A1	18 (13.0)		II (28.2%)
<i>GSTA1</i> *A2*B1a	11 (8.0)		
<i>GSTA1</i> *A2*B2	10 (7.2)		
<i>GSTA1</i> *A1*A1	17 (12.3)		III (47.8%)
<i>GSTA1</i> *A1*B1a	48 (34.8)		
<i>GSTA1</i> *A1*B2	1 (0.7)		
<i>GSTA1</i> *B1b*A2	3 (2.2)		IV (14.5%)
<i>GSTA1</i> *B1a*B1a	10 (7.2)		
<i>GSTA1</i> *B2*B1a	1 (0.7)		
<i>GSTA1</i> *B1b*A1	3 (2.2)		
<i>GSTA1</i> *B1a*B1b	3 (2.2)		
<b>Total</b>	138 (100)		

Abbreviations: *GSTA1*: glutathione S transferase alpha I. The proposed functional groups arise from in vitro reporter-gene assays and in vivo PK data performed in this study. Group I: considered as rapid metabolizers; Group II: considered as intermediate metabolizers; Group III: considered as normal metabolizers and Group IV: considered as slow metabolizers.

**Table 2: *GSTM1* and *GSTP1* genotypes and minor allele frequencies in the study population**

Genetic variant	Homozygous	Heterozygous
	for major allele N (%)	N (%)
<i>GSTM1</i> null *	73 (52.9)	-
<i>GSTP1</i> 313A>G	52 (37.7)	69 (50)
<i>GSTP1</i> 341C>T	117 (84.8)	18 (13)

Abbreviations: *GSTM1*: glutathione S transferase Mu1; *GSTM1* null- homozygous individuals for deletion; *GSTP1*: glutathione S transferase Pi1. \*Distinction cannot be made between *GSTM1* non-null heterozygous and homozygous individuals by the method used in the study, therefore observed frequencies could not be provided. *GSTM1* null individuals are considered as homozygous for major allele.



**Figure 2: Pharmacokinetic parameters of BU and dose requirement in relation to *GSTA1* functional diplotype groups and *GSTM1* genotypes. A. Busulfan first dose clearance (CL, in ml/min/kg) against *GSTA1* diplotypes B. Busulfan first dose CL in females only against *GSTA1* genotypes. C. Dose requirement (ratio of adjusted to initial dose) against *GSTA1* diplotypes. D. Cumulative AUC (mg.h/L) against *GSTA1* diplotypes. CHU Sainte-Justine patients only were included for analysis presented in C and D. Diplotype groups II and III were combined into a single group in C and D. E. Busulfan first dose clearance in children above 4 yrs of age against *GSTM1* genotypes. DELGSTM = Deleted *GSTM1* gene. Number of patients and p values are depicted on the plots.**

**Table 3: Relationship between GST genotypes and the clearance in univariate and multivariate linear regression**

	Variables	p	B	R <sup>2</sup>	Model
All patients	<i>GSTAI</i>	0.009	-0.31	5	Univariate
	<i>GSTAI</i>	0.01	-0.27	28	Multivariate
	Age	<0.0005	-0.09		
	Sex	0.09	0.3		
Girls only	<i>GSTAI</i>	<0.0005	-0.54	19	Univariate
	<i>GSTAI</i>	0.006	-0.35	46	Multivariate
	Age	<0.0005	-0.1		
Group I and IV	<i>GSTAI</i>	0.005	-0.37	23	Univariate
	<i>GSTAI</i>	0.02	-0.28	42	Multivariate
	Age	0.004	-0.1		

Co-variables include age (continuous), sex (dichotomized), conditioning regimen (busulfan-cyclophosphamide vs others) and diagnosis (malignant versus non-malignant); Co-variables with p<0.1 were retained in final model. When all patients and girls only were analyzed, *GSTAI* included all 4 diplotype groups; B, unstandardized coefficient, R<sup>2</sup>, % of variability explained by the genotype or the model (in multivariate analysis).

**Table 4: Relationship between GST genotypes and other variables with clinical outcomes in univariate and multivariate logistic regression**

	Clinical outcome	Variables	p	OR (95% CI)	R <sup>2</sup>	Model
A	SOS	<i>GSTAI</i>	<0.0005	8.5 (2.6-28.2)	16.7	Univariate
		<i>GSTAI</i>	0.001	9.0 (2.6-31)	21	Multivariate
		Age	0.07	1.1 (1.0-1.2)		
	aGvHD 1-4	<i>GSTAI</i>	0.001	5.2 (1.9-14.5)	14.1	Multivariate with genotypes only
		<i>GSTP1</i>	0.08	2.7 (0.9-7.9)		
		<i>GSTAI</i>	0.001	6.0 (2.1-17.4)	19.4	Multivariate
		<i>GSTP1</i>	0.03	3.6 (1.1-11.4)		
	Conditioning	0.02	0.3 (0.1-0.8)			
	TRT	<i>GSTAI</i>	0.001	11.8 (2.6-53.3)	15.4	Univariate
		<i>GSTAI</i>	0.001	12.7 (2.8-58.2)	22.3	Multivariate
		Age	0.008	1.1 (1.0-1.2)		
	HC	<i>GSTM1</i>	0.005	3.9 (1.5-10.0)	10.1	Univariate
		<i>GSTM1</i>	0.002	6.6 (2.0-22.2)	47.1	Multivariate
		Age	<0.0005	1.3 (1.1-1.4)		
Conditioning		0.06	9.3 (0.9-96.4)			
Diagnosis		0.1	2.8 (0.8-10.2)			
B	aGvHD 1-4	<i>GSTAI</i>	0.003	4.8 (1.7-13.5)	17.5	Multivariate
		<i>GSTP1</i>	0.06	2.8 (0.9-8.6)		
		Css	0.05	1.0 (1-1)		
	TRT	<i>GSTAI</i>	0.003	10.4 (2.3-47.8)	23.8	Multivariate
		Css	0.003	1 (1-1)		
	HC	<i>GSTM1</i>	0.005	4.1 (1.5-10.9)	19.1	Multivariate
		Css	0.004	1 (1-1)		

In A: co-variables include age, sex, diagnosis and conditioning regimen; in B: co-variable is Busulfan exposure represented as Busulfan Steady state concentration (Css). Co-variables with p<0.1 were retained in final model. Dichotomized variables were *GSTP1* (GG vs others), *GSTAI* (group IV vs others), *GSTM1* (non-null vs null), conditioning regimen (busulfan-cyclophosphamide vs others) and diagnosis (malignant versus non-malignant) whereas Css and age were continuous variables, OR, odds ratio, CI, confidence interval, R<sup>2</sup>, % of variability explained by the genotype or the model (in multivariate analysis).


in *group I* had on average a higher dose requirement compared to the other patients, whereas *group IV* cases had on average very little change from the initial dose ( $p = 0.03$ , Figure 2c). Cumulative AUC was also significantly associated in an additive manner with four diplotype groups with the highest exposure seen in the *group IV* ( $p = 0.01$ , Figure 2d).

Genotype frequencies for *GSTM1* and *GSTP1* variants are summarized in Table 2. When all patients were analyzed there was no significant association between PK and *GSTP1* or *GSTM1* genotypes (Table 3). But BU CL was associated with *GSTM1* genotypes in children above 4 years of age (Figure 2e). *GSTAI* diplotypes correlated with different ethnicities with *group I* being more frequent in other populations than in Caucasians ( $p < 0.0005$ ). Among non-genetic factors, CL adjusted for weight correlated significantly with age ( $p < 0.0005$ ). Age ( $p < 0.0005$ ), gender ( $p = 0.09$ ) and *GSTAI* diplotypes ( $p = 0.01$ ) were retained in the final multivariate linear model that explained 28% of overall variability in BU CL (Table 3). The diplotype contribution was relatively minor (5%) when all diplotypes and all patients are included in the analysis. However, when all girls ( $n = 64$ ) or patients

with diplotype *groups I* and *IV* representing the extreme of CL distribution ( $n = 33$ ) were considered, diplotype contribution increased to 19% and 23%, respectively, and the model explained 46% and 42% of variability in CL.

### Pharmacogenetics vs HSCT-related toxicities

Analyses between HSCT-related toxicities and the four *GSTAI* diplotype groups revealed a strong association with Sinusoidal Obstruction Syndrome (SOS) ( $p < 0.0005$ ; Figure 3a), whereby *Group IV* carriers had seven-fold higher risk of SOS (HR = 7.1; 95% CI: 2.5-20.4) compared to patients with other *GSTAI* diplotypes. Likewise, *group IV* carriers were also associated with the highest risk of acute Graft versus Host Disease (aGvHD), grades 1-4 ( $p < 0.0005$ , Figure 3b) and with Treatment Related Toxicity (TRT: combining SOS, hemorrhagic cystitis, lung toxicity and aGvHD grades 1-4,  $p < 0.0005$ , Figure 3c). The association between *GSTAI* diplotypes and TRT was also maintained if aGvHD grades 2-4 were included in the analysis rather than all grades of aGvHD ( $p = 0.03$ , Figure 3d). Individuals with *group IV* who received BU-cyclophosphamide conditioning regimen had



**Figure 3: Incidence of SOS, aGvHD and TRT in relation to *GSTAI* functional diplotype groups.** Cumulative incidences of **A.** sinusoidal obstruction syndrome (SOS), **B.** acute graft versus host disease (aGvHD) 1-4, **C.** treatment related toxicity (TRT) including aGvHD 1-4 and **D.** TRT including aGvHD 2-4. Results plotted for diplotype *group IV* (*IV+*) versus *groups I, II & III* (*IV-*). **E.** Overall survival (OS) in relation to *GSTAI* extreme diplotype status (*group I* vs. *group IV*), in patients who received busulfan-cyclophosphamide conditioning regimen. Total number of patients represented by each curve with number of patients with indicated toxicities in parenthesis, and p value are depicted on each plot; *group IV* associated hazard ratios are depicted below each plot. **F.** Association of TRT with diplotype *group IV* in a competing events risk analysis. *IV+* and *IV-* indicates the presence of this *GSTAI* diplotype group. Competing events for TRT incidence were: death and relapse. p values for the difference in cumulative incidence of TRT, death, and relapse, between haplotype groups (*IV* vs others) is 0.000003, 0.3 and 0.5, respectively.

**Table 5: Participating centers, demographic and transplantation characteristics**


Characteristics of the study group		Patients	
		N	%
<b>Centers</b>	<i>CHU St-Justine, Montreal (Canada)</i>	83	60.1
	<i>SickKids Hospital, Toronto (Canada)</i>	25	18.1
	<i>Geneva University Hospital, Genève (Switzerland)</i>	4	2.9
	<i>Robert Debré University Hospital, Paris (France)</i>	12	8.7
	<i>University Medical Center, Utrecht (Netherlands)</i>	14	10.1
<b>Gender</b>	<i>Male</i>	74	53.6
	<i>Female</i>	64	46.4
<b>Ethnicity (n = 135)</b>	<i>Caucasian</i>	99	73.3
	<i>Native American</i>	4	3
	<i>African-American</i>	20	14.8
	<i>Asian</i>	9	6.7
	<i>Middle East</i>	3	2.2
<b>Diagnosis</b>	<i>ALL/AML</i>	43	31.2
	<i>MDS</i>	31	22.5
	<i>ALL</i>	12	8.7
	<i>Biphenotypic acute leukemia</i>	1	0.7
	<i>Myeloproliferative syndrome</i>	1	0.7
	<i>Non-Malignancies</i>	14	10.1
<b>HLA compatibility</b>	<i>Hemoglobinopathy</i>	13	9.4
	<i>Immunodeficiencies</i>	12	8.7
	<i>Hemophagocytic syndrome</i>	8	5.8
	<i>Metabolic disease</i>	3	2.2
	<i>BMFS</i>	30	21.7
<b>Stem Cell Source</b>	<i>MUD</i>	6	4.3
	<i>MM – related donor</i>	53	38.4
	<i>MM – unrelated donor</i>	49	35.5
	<i>HLA identical sibling</i>	59	42.8
<b>Myeloablative Conditioning</b>	<i>BM</i>	4	2.9
	<i>PBSC</i>	74	53.6
	<i>BM + PBSC</i>	1	0.7
	<i>BU/CY</i>	106	76.8
	<i>BU/Mel</i>	2	1.4
<b>Serotherapy</b>	<i>BU/CY/Mel</i>	15	10.9
	<i>BU/CY/VP16</i>	15	10.9
	<i>No</i>	37	26.8
	<i>ATG</i>	99	71.7
<b>GvHD Prophylaxis</b>	<i>Campath</i>	2	1.4
	<i>CSA + steroids</i>	50	44.64
	<i>CSA + MTX</i>	51	45.53
	<i>CSA</i>	9	8.03
	<i>No</i>	2	1.8
	<b>Median</b>	<b>Range</b>	
<b>BM:</b>			
	<i>Nucleated cells (x10<sup>8</sup>/Kg)/n=57</i>	4.91	(0.11-23.2)
	<i>CD34 cells (x10<sup>8</sup>/Kg)/n=39</i>	0.05	(0.00024-1.3)
<b>Cord Blood:</b>			
	<i>Nucleated cells (x10<sup>8</sup>/Kg)/n=74</i>	1.2	(0.7-14.8)
	<i>CD34 cells (x10<sup>8</sup>/Kg)/n=73</i>	0.0035	(0.0001-0.14)
<b>PBSC:</b>			
	<i>Nucleated cells (x10<sup>8</sup>/Kg)/n=4</i>	3.49	(0.01-47.1)
	<i>CD34 cells (x10<sup>8</sup>/Kg)/n=4</i>	0.17	(0.014-0.31)
	<i>Age (years)</i>	5.8	(0.1-19.9)
	<i>Weight (kg)</i>	20.05	(4-87.9)
	<i>Height (cm)</i>	112.5	(51-183)
	<i>BMI (Kg/m<sup>2</sup>)</i>	17.43	(12.9-29.5)
	<i>BSA (m<sup>2</sup>)</i>	0.8	(0.24-2.1)

Abbreviations ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; ATG: anti-thymocyte globulin; BM: bone marrow; BMFS: bone marrow failure syndrome; BMI: Body mass index; BSA: body surface area; BU: busulfan; Campath: Alemtuzumab; CY: cyclophosphamide; CSA: cyclosporine; Flu: fludarabine; MDS: myelodysplastic syndrome; Mel: melphalan; MM: mismatch; MRD: matched related donor; MUD: matched unrelated donor; MTX: methotrexate; CSA: cyclosporine; SD: sibling donor; GvHD: graft-versus-host-disease; PBSC: peripheral blood stem cells; VP16:etoposide


also lowest overall survival (OS) compared to *group I* ( $p = 0.02$ , Figure 3e). This was likely due to the high TRT rates, since when the cumulative incidence of competing events analysis was performed, with TRT, relapse and death as competing events, only the association with TRT remained significant ( $p < 0.0005$ , Figure 3f).

Regarding the remaining *GST* genes, *GSTP1* (*GG 313*) was associated with a higher probability of aGvHD 1-4 ( $p = 0.01$ , Figure 4a). This effect was independent of *GSTA1* haplotype and each genotype (*GSTP1 GG 313* and *GSTA1 group IV*) independently and combined contributed to aGvHD development with highest risk seen in individuals with both risk genotypes ( $p < 0.0005$ , Figure 4b). Incidence of hemorrhagic cystitis was higher in *GSTM1 non-null* individuals compared to patients with *GSTM1* deletion ( $p = 0.003$ , Figure 4c). C<sub>ss</sub> after first dose categorized according to historical target correlated with event free survival (EFS), OS and TRT ( $p < 0.0005$ ) (Figure 5a). C<sub>ss</sub> above 900 ng/mL was associated with

TRT irrespective of diplotype groups (Figure 6a), whereas high risk of TRT for C<sub>ss</sub> below 900 ng/mL was evident only for *group IV* carriers (Figure 6b). In multiple logistic regression models the best predictors of SOS and TRT were age and *GSTA1* diplotypes (Table 4a), explaining 21-22% of variability of which 15-17% was attributed to *GSTA1*. For aGvHD, the final model included conditioning regimen, *GSTA1* and *GSTP1* that explained 19% of the variability of which 14% was accounted for by the two GSTs (Table 4a). Multivariate modelling for hemorrhagic cystitis included *GSTM1*, diagnosis, conditioning regimen and age, explaining 47% of variability of which 10% was attributed to *GSTM1* (Table 4a). BU exposure was significantly associated with aGvHD, TRT and hemorrhagic cystitis and was further analyzed together with genotypes/diplotypes in a multivariate model in which both variables remained significant predictors of respective outcomes (*GSTA1*,  $p = 0.003$ , *GSTM1*,  $p = 0.005$ , C<sub>ss</sub>  $p \leq 0.05$ , (Table 4b).



**Figure 4: Complications of HSCT in relation to *GSTP1* genotypes and *GSTA1* diplotypes.** A. Acute GvHD 1-4 incidence according to *GSTP1* c.313A>G genotypes; and B. Acute GvHD 1-4 incidence according to combinatory *GSTA1-GSTP1* status. A plus sign represents the risk genotypes, which is presence of *GSTP1*\*GG and/or *GSTA1* diplotype *group IV*. C. Hemorrhagic Cystitis (HC) incidences in relation to *GSTM1* Null and Non-null genotype.



**Figure 5: Busulfan plasma exposure and clinical outcomes of HSCT.** Incidences of event-free survival (EFS), overall survival (OS), and treatment related toxicity (TRT) plotted against 3 groups based on first dose steady state concentration (C<sub>ss</sub>) i.e. <600, 600-900 and > 900 ng/mL in all patients ( $n = 138$ ). Total number of patients in each group (number of patients with events) are depicted on all plots.  $P$  values are shown on the plots.

**Table 6: Administration of BU and Pharmacokinetic parameter estimation per Center (n=138)**

Centers	Busulfan Initial IV Dose	Busulfan, Dose adjusted	Method for estimating Busulfan concentration	Therapeutic Drug Target	The determination of pharmacokinetic parameters, estimated from the first dose.
CHU St-Justine, Canada	0.8mg/kg/dose (infants≥3months and <1 year of age) 1 mg/kg/dose (children≥1 year and <4 years old) 0.8mg/kg/dose (children≥4 years old)	5th dose	HPLC/LC-MS/MS	Css target = 600–900 ng/mL	Non-compartmental analysis (WinNonlin, version 3.1, Pharsight)
Geneva University Hospital, Switzerland	0.8mg/kg/dose (infants≥3months and <1 year of age) 1 mg/kg/dose (children≥1 year and <4 years old) 0.8mg/kg/dose (children≥4 years old)	4th dose	LC-MS/MS	Css target = 600–900 ng/mL	Non-compartmental analysis (WinNonlin, version 3.1, Pharsight)
Leiden University Medical Center Netherlands	0.8 to 1mg/kg/dose (infants≥4 years of age); 1mg/kg/dose (infants<4 years old)	5th or 9th dose	HPLC/LC-MS/MS	Css target = 740–910 ng/mL  Then the dose was only adjusted by a maximum of 1 mg/kg every 6 hours.	Non-compartmental analysis (WinNonlin, version 3.1, Pharsight)
Robert Debré University Hospital, France	<9kg (1mg/kg/dose) 9≥to<16kg (1.2mg/kg/dose) 16≥to<23kg (1.1mg/kg/dose) >23to<34kg (0.95mg/kg/dose) >34kg (0.8mg/kg/dose)	7th or 9th dose	GC-MS	Css target = 600-1026 ng/mL	Non-compartmental analysis (WinNonlin, version 3.1, Pharsight)
SickKids Hospital, Canada	<9kg (1mg/kg/dose) 9 to <16kg (1.2mg/kg/dose) 16 to 23kg (1.1mg/kg/dose) 23 to 34kg (0.95mg/kg/dose) >34kg (0.8mg/kg/dose)	3rd or 4th dose	GC-ECD	Css target = 889 ng/mL	Limited Sampling Strategy or Trapezoidal rule to calculate AUC

Evaluation of Pharmacokinetic parameter estimations: A cross calibration study was conducted by our group with the collaboration of Pierre Fabre Laboratories between all centers participating in the study to validate analytical method used to determine the PK parameters from the first dose (data available upon request). Only centers with the measured BU concentrations falling within ± 20% of the therapeutic drug target concentrations were included for analysis of PK parameters. Abbreviations: AUC: Area under the curve; C<sub>ss</sub>: Steady state concentration; GC-MS: Gas Chromatography Mass Spectrometry; GC-ECD: Gas Chromatography with Electron Capture Detector; HPLC: High Performance Liquid Chromatography; LC-MS/MS: Liquid chromatography–mass spectrometry

**Table 7: Busulfan pharmacokinetic parameters observed in the study subjects after administration of the first dose.**

Parameter for all centers	Median (range) N=138	Median (range) CHUSJ only N=83	Median (range) Other cohorts N=55
C <sub>max</sub> (ng/mL)	890.5 (515.9-1709)	844.0 (545.0-1298.0)	1004.8 (515.9-1709)
C <sub>ss</sub> (ng/mL)	667.7 (325-1238)	596.0 (325.0-1227.0)	711.0 (403.0-1238.0)
AUC (mg.h/L)	3.5 (1.82-7.31)	3.3 (1.8-7.2)	4.2 (2.2-7.3)
Clearance (mL/min/kg)	4.1 (1.8-7.2)	4.2 (1.8-7.2)	3.7 (1.8-6.3)

C<sub>max</sub>: maximum plasma concentration; C<sub>min</sub>: Minimum plasma concentration; C<sub>ss</sub>: Steady state plasma concentration; AUC: Area under the curve; CHUSJ: Center Hospitalier universitaire Sainte-Justine

## DISCUSSION

This study is conducted in a multicenter pediatric HSCT cohort and provides the first evidence for the association of functional *GSTA1* diplotype groups with BU PK and clinical outcomes. Several studies including our own (summarized in Supplementary Table 1), performed in childhood and adult patients who received either iv or oral BU, have previously demonstrated an association between first dose PK and *GSTA1* gene [3, 15-20, 22-26, 28, 33]. These studies, however, rarely included clinical outcome and none (except the one conducted by our group) included *GSTA1* sub-haplotypes. There are only two studies [19, 26] that are comparable to the present

report since they were conducted in childhood patients diagnosed mainly with malignancies who received i.v. BU-cyclophosphamide combination. Still, genetic association with clinical outcomes were not investigated in both of these studies and were also limited by the sample numbers. Overall, positive associations between *GSTA1* gene and PK are characterized by higher BU exposure in *\*B* individuals and lower in *\*A* carriers, which is functionally driven by a -52 G>A promoter SNP (in complete linkage disequilibrium with -69 C>T and -567 A>T) delineating *\*A* and *\*B* haplotypes [34]. *GSTA1* gene has an additional three SNPs within its promoter further diversifying haplotypes into subgroups that can potentially contribute to *GSTA1* functionality. Using a gene reporter assay, we

**Table 8: Clinical outcomes observed in the study subjects**


Clinical outcomes	Cumulative incidence		Day of onset		
	N	(%)	Median	(range)	
Neutrophil recovery (Day 100)	123	(89.1)	19	(1-50)	
Platelet recovery (Day 180)	106	(77)	40	(16-173)	
Sinusoidal Obstruction Syndrome (SOS)	14	(10.1)	16	(3-47)	
aGvHD (grade 1-4)	43	(31.2)	36	(10-162)	
aGvHD (grade 2-4)	27	(19.6)	44	(11-162)	
Lung toxicity	7	(5.1)	45	(4-166)	
Hemorrhagic cystitis	26	(18.8)	24.5	(2-113)	
Death	38	(27.5)	127	(15-365)	
Combined Treatment Related Toxicity (TRT)	55	(39.8)	136	(2-180)	
Rejection	12	(8.7)	52.5	(34-246)	
Event	45	(33)	70	(15-364)	
% of donor cell chimerism Day 100 (n=112)					
	>95%	66	(58.9)	96	(24-132)
	≥50%-95%	13	(11.6)	100	(31-118)
	<50%	19	(17)	95	(28-156)

Abbreviation: aGvHD - acute Graft versus Host Disease

defined for the first time the promoter activity of each subgroup showing that *\*A1* could be classified as a normal metabolizer, *\*A2* and *\*A3* as rapid metabolizers, whereas slow metabolizing capacity was assigned to *\*B1a* and *\*B2* and very slow to *\*B1b*. Four major diplotype groups that reflected well *GSTA1*-PK relationship were defined. *Group I* (rapid metabolizers) was mostly represented by *\*A2\*A2* diplotype and group IV (slow metabolizers) by *\*B1a\*B1a* diplotype and the presence of *\*B1b* haplotype. *Group I* correlated with highest and *group IV*, with lowest CL. The relationship observed with *group I* is in accordance

with our previous study [20, 33] which reported higher BU CL in *\*A2 \*A2* individuals. More evident association of diplotype groups with PK was seen in girls, also in accordance with previous observation [20], which could be due to the higher level of *GSTA1* in females compared to males particularly in liver cytosol [35, 36], or to more prominent induction and inhibition of *GSTA1* [37].

Association of *GSTA1* with PK was also reflected in *GSTA1* association with dose requirements and with cumulative AUC, as seen by the analysis performed in CHU Sainte Justine patients. Indeed, on average there was



**Figure 6: Treatment related toxicity (TRT) in relation to both 1st dose C<sub>ss</sub> and *GSTA1* groups.** TRT (all cases combined) plotted against **A.** Busulfan C<sub>ss</sub> below 900 ng/mL or **B.** C<sub>ss</sub> above 900 ng/mL, dependent on whether patients are in *GSTA1* diplotype *group I, II, III (IV-)* or *IV (IV+)*. Total number of patients in each group with number of patients with TRT in brackets is depicted on all plots. Hazard ratio for group IV is depicted for plot (A) only.

no dose reduction in *group IV*, whereas in *group I*, in spite of the dose increase in most of these patients, cumulative AUC stayed the lowest. For *group IV* higher cumulative AUC's may suggest that 1) Initial doses were too high for some patients; 2) Subsequent dose adjustments in these patients were not sufficient and thus dose reduction needs to be greater; 3) Toxic damage may have already been inflicted after first doses, 4) Possibility of a significant reduction in CL in *group IV* upon time. This emphasizes the need to adjust first dose according to genotype rather than adjusting only after therapeutic drug monitoring. Our results are in accordance with a study looking at oral BU dose requirement based on *GSTAI* haplotypes [18] in which the first two oral doses were kept constant and later doses were adjusted to target a C<sub>ss</sub> of 900 ng/mL (AUC of 5.4 mg.h/L), but despite dose adjustments, the average BU C<sub>ss</sub> of the 3 dosing intervals remained significantly higher among *GSTAI\*B* carriers [18].

We did not observe an association of *GSTM1* with PK when all patients were analyzed. However, *GSTM1*'s involvement in BU PK could be quantitatively and qualitatively different in infants and toddlers (0-4 years old) compared to children and adolescents (4-18 year olds) as a consequence of developmental changes in gene expression as reported in ontogeny data [38]. This shows the limitation of the model with CL in L/h/kg that does not capture well the data for all patients over a varied age range. In future studies a more physiological related PK model should be used [39, 40]. Indeed, similar to our previous finding [20] patients above 4 years of age with *GSTM1* null genotype had lower CL (Figure 2e). Bremer and colleagues [18] reported that *GSTAI\*B\*B* individuals who are also *GSTM1* null tend to have higher C<sub>ss</sub> after oral BU and patients with a combined *GSTAI\*B\*B*, *GSTM1* null and *GSTT1* null presented the highest C<sub>ss</sub> levels of all genotype groups. We did not notice the combined effect of *GSTAI* diplotypes and *GSTM1* null genotype on the PK. Oral BU used in the study of Bremer et al., [18] usually resulting in larger inter-individual variability, might have also contributed to this difference.

Attention should be given to the association of *GSTAI* diplotypes with clinical outcomes, given the paucity of such data in the literature [15-18, 20, 25, 27, 29, 31, 32], summarized in Supplementary Table 1. Interestingly, despite the fast BU metabolizing capacity and concentrations falling below the target range individuals with rapid metabolizing capacity (*GSTAI group I*) showed a protective role in terms of OS, likely related to lower probability of TRT. This was most evident in individuals who received BU-cyclophosphamide conditioning regimen. A similar association was seen in a study performed in a Chinese population, where the *GSTAI\*A\*A* carriers showed significantly lower AUC than the *GSTAI\*A\*B* group with minimal toxicity when BU was administered once daily, highlighting the protective role of *GSTAI\*A\*A* [15]. This is also in accordance

with our previous report [20] in which patients with two copies of haplotype *\*A2* had better EFS. On the other hand, individuals in group IV with slow metabolizing capacity demonstrated lower OS. These reductions seem to be related to higher frequency of TRT reflected by more frequent SOS and aGvHD suggesting that these patients are at a higher risk of TRT and might benefit from adjustment of the target AUC and initial dose reduction.

The association of *GSTAI* gene with clinical outcomes might be related to *GSTAI*-PK relationship or might reflect additional involvement of *GSTAI* beyond BU metabolism. When both *GSTAI* diplotype groups and BU exposure were entered in a multivariate model, *GSTAI* diplotypes were the only predictors of SOS, whereas aGvHD and combined TRT were predicted by both BU exposure and *GSTAI* diplotypes independently. This was also reflected by the fact that C<sub>ss</sub> above 900 ng/mL was associated with TRT irrespective of diplotype groups, whereas high risk of TRT for C<sub>ss</sub> below 900 ng/mL was evident only for group IV carriers. The patients were recruited during a large time span, which could have influenced some of the associations observed, however, neither prophylactic measures nor TRT incidences differed significantly over time. *GSTAI* also participates in the metabolism of cyclophosphamide [41] possibly explaining modulation of associations of clinical outcomes in BU-cyclophosphamide conditioning regimen. Interestingly in lupus nephritis patients, *GSTAI\*B* genotypes have higher exposure to activated cyclophosphamide metabolites [42]. Therefore, these vulnerable patients might benefit from administration of cyclophosphamide before BU or alternative conditioning regimens such as BU/Fludarabine. Non-catalytic functions of the GST enzymes could be considered as well, for example *GSTM1* and *GSTP1* have been linked to inhibition of the mitogen-activated protein (MAP) kinase pathway [43] modulating apoptotic signalling. Additionally, glutathione S-transferase family has the potential to behave as minor histocompatibility antigens (miHA). miHA disparities have been attributed to GvHD in the HLA-matched transplantation setting [44] potentially explaining independent effect of *GSTAI* and *GSTP1* genotypes in aGvHD susceptibility.

The association observed with *GSTM1* and hemorrhagic cystitis could derive from the interaction between busulfan and cyclophosphamide affecting the clearance of cyclophosphamide metabolites such as acrolein, which can be damaging to the kidney and bladder epithelium [45]. *GSTM1* non-null carriers might deplete the glutathione pool, limiting conjugation of these metabolites by other specific GSTs such as *GSTP1*. The additional role of *GSTM1* in determining clinical outcomes of HSCT, which is distinct from its role in BU metabolism is also a possible explanation for the higher incidences of early mortality observed in the study by Bremer et al. for *GSTM1* non null individuals receiving BU-cyclophosphamide regimen [18].

## CONCLUSION

We provide evidence for an association of *GSTA1* diplotypes with BU PK and clinical outcomes of HSCT supported by functional studies. *GSTA1* diplotypes can explain in some models ~20% of the variability seen in BU CL and can contribute to HSCT -related complications acting within and beyond BU metabolism. Prior genotyping may be helpful in deciding on BU first dose, thus optimizing therapeutic drug monitoring and decreasing TRT, which is particularly important for *GSTA1* group IV carriers. It might also help to define each patient risk to toxicity and introduce the possibility of individualised prophylaxis. Other GST polymorphisms seem also to contribute to HSCT-related toxicities and may include additional mechanisms. Further studies are needed to define prospectively how to adjust dose according to the genotype, including non-genetic factors and different BU administration schedules.

## MATERIALS AND METHODS

### Patients

The study includes 138 pediatric patients who underwent allogeneic HSCT with i.v. BU as part of a myeloablative conditioning regimen from five different centers in Europe and Canada (Geneva, Leiden, Montreal, Paris, Toronto), recruited between May 2000 and April 2013. The Institutional Review Board at each center approved the study and all patients and/or parents provided informed consent. Details of inclusion criteria are available at Clinicaltrials.gov site (NCT01257854). Patients' characteristics are provided in Table 5.

### Sampling, genotyping, administration of BU and PK estimation

GST genotyping was performed according to the previously described procedures [33, 46]. BU was administered every 6h as a 2 h infusion for a total of 16 doses. The first dose was either age or weight-based and dose adjustment (based on the first dose PK parameter estimates) was performed on the 3<sup>rd</sup>, 4<sup>th</sup>, 5<sup>th</sup>, or 9<sup>th</sup> dose onwards as detailed on Table 6 which summarizes the dosing schedule followed by each center. The median BU PK parameters observed in the study subjects after administration of the first dose are summarized in Table 7.

Clinical outcomes (Table 8) were defined as per the standard guidelines of the European Society for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research as detailed in previous reports [6, 20]. TRT was defined as

the occurrence of first toxicity, either SOS, aGvHD, lung toxicity or HC. An event was defined as graft rejection, relapse or death from any cause.

### Reporter-gene assay

Plasmid constructs were prepared by a gene assembly service (GeneScript, Piscataway, USA). DNA region from -1275 to +126 relative to the translational start codon was cloned into pGL4.10 (Promega, Maddison, USA). HepG2 cells were co-transfected with the pGL4.10 *GSTA1* constructs (with site specific mutations underlying *GSTA1* haplotypes) and the pRL-SV40 vector (Promega) that codes for *Renilla* luciferase for transfection control and normalisation. Difference in promoter activity between haplotypes was assessed by t-test or ANOVA.

### Statistical analyses

BU clearance (mL/min/kg), ratio of adjusted to initial dose and cumulative AUCs were compared across genotypes or diplotype groups using non-parametric tests or linear regression. Cumulative incidences of OS and EFS and of adverse events were estimated in relation to the genotype/ diplotype groups, using Kaplan-Meier framework and log-rank test. Univariate Cox regression was used to estimate hazard ratios. The analyses were also performed by cumulative incidence of competing events and the difference among groups estimated by Gray's test [47]. The relationship of *GST* with CL and clinical outcomes was additionally explored through stratified and multivariate analysis. Stratified analyses were performed according to age, gender, diagnosis and conditioning regimen. Multivariate analysis included co-variables that were either significantly associated with outcome studied, correlated with genotypes/diplotypes or modulated genotype-phenotype associations: age, gender, diagnosis, conditioning regimen, ethnicity and BU exposure. The allele and genotype frequencies, and Hardy-Weinberg equilibrium were analysed using Haploview [48]; haplotypes were resolved using PHASE [49]. Statistical analyses were performed using IBM® SPSS® statistics (version 19, SPSS Inc, NY) and EZR (Version 1.31) [50].

### Abbreviations

HSCT: Hematopoietic stem cell transplantation; GST: glutathione S transferase; GSTA1: glutathione S transferase Alpha1; GSTP1: glutathione S transferase Pi 1; GSTM1: glutathione S transferase Mu 1; GSTT: glutathione S transferase Theta; BU: Busulfan; AUC: Area under the curve; C<sub>ss</sub>: Stead state concentration; PK: pharmacokinetics; TRT: Treatment Related Toxicity; SOS: Sinusoidal Obstruction Syndrome; aGvHD: acute Graft

versus Host Disease; HepG2: Human hepatoma; OS: Overall survival; EFS: Events Free Survival.

### Author contributions

M.A, P.HDC, CRS.U, T.N, MA.R, V.M, L.L, Y.T performed experiments, M.A, P.HDC, CRS.U, MA.R and M.K performed the analysis, M.A and MK designed the research, M.A, P.HDC, CRS.U and M.K drafted the article; all authors contributed to the interpretation of data and revised the manuscript critically.

### ACKNOWLEDGMENTS

This study was performed under the supervision of the Swiss National Science Foundation and CANSEARCH foundation. We warmly thank the patients and their parents for consenting to participate in this study. We also thank R. Lo Piccolo, S. Mezziani, M-F.Vachon, and M. Cortier for the help in this study as well as N. Von Der Weid and the Swiss Pediatric Oncology Group for being the sponsors of this study.

### CONFLICTS OF INTEREST

H.B has acted as a consultant for Jazz Pharmaceuticals and obtained an education grant from them. H.B also acted as a consultant for Seattle Genetics. The authors declare that they have no other financial relationship(s) to disclose.

### FUNDING

This study was supported by grants from the Swiss National Science Foundation (Grant number153389), CANSEARCH Foundation, the Geneva Cancer League, the Dr. Henri Dubois-Ferrière Dinu Lipatti Foundation, and Foundation of Charles-Bruneau Cancer Center.

### Editorial note

This paper has been accepted based in part on peer-review conducted by another journal and the authors' response and revisions as well as expedited peer-review in Oncotarget.

### Supplementary Data

Supplementary Data available in Supplementary Files.

## REFERENCES

1. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschoner WE, Bias WB, Braine HG, Burns WH, Elfenbein GJ, Kaizer H. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. *The New England Journal of Medicine*. 1983; 309: 1347-53. doi: 10.1056/NEJM198312013092202.
2. Hassan M, Andersson BS. Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. *Pharmacogenomics*. 2013; 14: 75-87. doi: 10.2217/pgs.12.185.
3. Huezo-Diaz P, Uppugunduri CR, Tyagi AK, Krajcinovic M, Ansari M. Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in children. *Current Drug Metabolism*. 2014; 15: 251-64.
4. Bartelink IH, Lalmohamed A, Van Reij EML, Dvorak CC, Savic RM, Zwaveling J, Bredius RGM, Egberts ACG, Bierings M, Kletzel M, Shaw PJ, Nath CE, Hempel G, et al. A New Harmonized Approach to Associate Busulfan Exposure with Survival and Toxicity after Hematopoietic Cell Transplantation in Children and Young Adults: a Multicenter Retrospective Cohort Analysis. *The Lancet Haematology*. 2016; 3: e526-e36.
5. Zao JH, Schechter T, Liu WJ, Gerges S, Gassas A, Egeler RM, Grunebaum E, Dupuis LL. Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning. *Biology of Blood and Marrow Transplantation*. 2015; 21: 1471-8. doi: 10.1016/j.bbmt.2015.05.006.
6. Ansari M, Theoret Y, Rezgui MA, Peters C, Mezziani S, Desjean C, Vachon MF, Champagne MA, Duval M, Krajcinovic M, Bittencourt H, Pediatric Disease Working Parties of the European B, Marrow Transplant G. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation. *Therapeutic Drug Monitoring*. 2014; 36: 93-9. doi: 10.1097/FTD.0b013e3182a04fc7.
7. Baker KS, Bostrom B, DeFor T, Ramsay NK, Woods WG, Blazar BR. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia. *Bone Marrow Transplantation*. 2000; 26: 607-14. doi: 10.1038/sj.bmt.1702590.
8. Maheshwari S, Kassim A, Yeh RF, Domm J, Calder C, Evans M, Manes B, Bruce K, Brown V, Ho R, Frangoul H, Yang E. Targeted Busulfan therapy with a steady-state concentration of 600-700 ng/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant. *Bone Marrow Transplantation*. 2014; 49: 366-9. doi: 10.1038/bmt.2013.188.

9. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. *Drug Metabolism & Disposition*. 1996; 24: 1015-9.
10. Ramsay EE, Dilda PJ. Glutathione S-conjugates as prodrugs to target drug-resistant tumors. *Frontiers in Pharmacology*. 2014; 5: 181. doi: 10.3389/fphar.2014.00181.
11. Coles BF, Morel F, Rauch C, Huber WW, Yang M, Teitel CH, Green B, Lang NP, Kadlubar FF. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. *Pharmacogenetics*. 2001; 11: 663-9.
12. Bredschneider M, Klein K, Murdter TE, Marx C, Eichelbaum M, Nussler AK, Neuhaus P, Zanger UM, Schwab M. Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation. *Clinical Pharmacology & Therapeutics*. 2002; 71: 479-87. doi: 10.1067/mcp.2002.124518.
13. Board P, Coggan M, Johnston P, Ross V, Suzuki T, Webb G. Genetic heterogeneity of the human glutathione transferases: a complex of gene families. *Pharmacology & Therapeutics*. 1990; 48: 357-69.
14. Zimniak P, Nanduri B, Pikula S, Bandorowicz-Pikula J, Singhal SS, Srivastava SK, Awasthi S, Awasthi YC. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. *European Journal of Biochemistry*. 1994; 224: 893-9.
15. Yin J, Xiao Y, Zheng H, Zhang YC. Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients. *Bone Marrow Transplantation*. 2015; 50: 696-705. doi: 10.1038/bmt.2015.14.
16. Choi B, Kim MG, Han N, Kim T, Ji E, Park S, Kim IW, Oh JM. Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation. *Pharmacogenomics*. 2015; 16: 1585-94. doi: 10.2217/pgs.15.98.
17. Ansari M, Huezo-Diaz P, Rezgui MA, Marktel S, Duval M, Bittencourt H, Cappelli B, Krajcinovic M. Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients. *Bone Marrow Transplantation*. 2016; 51: 377-83. doi: 10.1038/bmt.2015.321.
18. Bremer S, Floisand Y, Brinch L, Gedde-Dahl T, Bergan S. Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning. *Therapeutic Drug Monitoring*. 2015; 37: 493-500. doi: 10.1097/FTD.0000000000000180.
19. ten Brink MH, van Bavel T, Swen JJ, van der Straaten T, Bredius RG, Lankester AC, Zwaveling J, Guchelaar HJ. Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation. *Pharmacogenomics*. 2013; 14: 1683-90. doi: 10.2217/pgs.13.159.
20. Ansari M, Rezgui MA, Theoret Y, Uppugunduri CR, Mezziani S, Vachon MF, Desjean C, Rousseau J, Labuda M, Przybyla C, Duval M, Champagne M, Peters C, et al. Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients. *Bone Marrow Transplantation*. 2013; 48: 939-46. doi: 10.1038/bmt.2012.265.
21. ten Brink MH, Wessels JA, den Hartigh J, van der Straaten T, von dem Borne PA, Guchelaar HJ, Zwaveling J. Effect of genetic polymorphisms in genes encoding GST isoenzymes on BU pharmacokinetics in adult patients undergoing hematopoietic SCT. *Bone Marrow Transplantation*. 2012; 47: 190-5. doi: 10.1038/bmt.2011.55.
22. Kim SD, Lee JH, Hur EH, Lee JH, Kim DY, Lim SN, Choi Y, Lim HS, Bae KS, Noh GJ, Yun SC, Han SB, Lee KH. Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation*. 2011; 17: 1222-30. doi: 10.1016/j.bbmt.2010.12.708.
23. Abbasi N, Vadnais B, Knutson JA, Blough DK, Kelly EJ, O'Donnell PV, Deeg HJ, Pawlikowski MA, Ho RJ, McCune JS. Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. *The Journal of Clinical Pharmacology*. 2011; 51: 1429-38. doi: 10.1177/0091270010382915.
24. Gaziev J, Nguyen L, Puozzo C, Mozzi AF, Casella M, Perrone Donnorso M, Gravina P, Sodani P, Marziali M, Isgro A, Simone MD, Andreani M, Formosa A, et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. *Blood*. 2010; 115: 4597-604. doi: 10.1182/blood-2010-01-265405.
25. Elhasid R, Krivoy N, Rowe JM, Sprecher E, Adler L, Elkin H, Efrati E. Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation. *Pediatric Blood & Cancer*. 2010; 55: 1172-9. doi: 10.1002/pbc.22739.
26. Johnson L, Orchard PJ, Baker KS, Brundage R, Cao Q, Wang X, Langer E, Farag-El Maasah S, Ross JA, Rimmel R, Jacobson PA. Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation. *The Journal of Clinical Pharmacology*. 2008; 48: 1052-62. doi: 10.1177/0091270008321940.
27. Kim I, Keam B, Lee KH, Kim JH, Oh SY, Ra EK, Yoon SS, Park SS, Kim CS, Park S, Hong YC, Kim BK. Glutathione

- S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. *Clinical Transplantation*. 2007; 21: 207-13. doi: 10.1111/j.1399-0012.2006.00624.x.
28. Kusama M, Kubota T, Matsukura Y, Matsuno K, Ogawa S, Kanda Y, Iga T. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. *Clinica Chimica Acta*. 2006; 368: 93-8. doi: 10.1016/j.cca.2005.12.011.
  29. Gaziev J, Isgro A, Mozzi AF, Petain A, Nguyen L, Ialongo C, Dinallo V, Sodani P, Marziali M, Andreani M, Testi M, Paciaroni K, Gallucci C, et al. New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation. *Pediatric Blood & Cancer*. 2015; 62: 680-6. doi: 10.1002/pbc.25376.
  30. Ten Brink MH, Swen JJ, Bohringer S, Wessels JA, van der Straaten T, Marijt EW, von dem Borne PA, Zwaveling J, Guchelaar HJ. Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients. *Pharmacogenetics and Genomics*. 2013; 23: 675-83. doi: 10.1097/FPC.000000000000007.
  31. Zwaveling J, Press RR, Bredius RG, van Derstraaten TR, den Hartigh J, Bartelink IH, Boelens JJ, Guchelaar HJ. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. *Therapeutic Drug Monitoring*. 2008; 30: 504-10. doi: 10.1097/FTD.0b013e3181817428.
  32. Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M, Krishnamoorthy R. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. *Blood*. 2004; 104: 1574-7. doi: 10.1182/blood-2003-11-3778.
  33. Ansari M, Lauzon-Joset JF, Vachon MF, Duval M, Theoret Y, Champagne MA, Krajcinovic M. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. *Bone Marrow Transplantation*. 2010; 45: 261-7. doi: 10.1038/bmt.2009.143.
  34. Morel F, Rauch C, Coles B, Le Ferrec E, Guillouzo A. The human glutathione transferase alpha locus: genomic organization of the gene cluster and functional characterization of the genetic polymorphism in the hGSTA1 promoter. *Pharmacogenetics*. 2002; 12: 277-86.
  35. Hoensch H, Morgenstern I, Peteret G, Siepmann M, Peters WH, Roelofs HM, Kirch W. Influence of clinical factors, diet, and drugs on the human upper gastrointestinal glutathione system. *Gut*. 2002; 50: 235-40.
  36. Mulder TP, Court DA, Peters WH. Variability of glutathione S-transferase alpha in human liver and plasma. *Clinical Chemistry*. 1999; 45: 355-9.
  37. Mitchell AE, Burns SA, Rudolf JL. Isozyme- and gender-specific induction of glutathione S-transferases by flavonoids. *Archives of Toxicology*. 2007; 81: 777-84. doi: 10.1007/s00204-007-0210-9.
  38. Strange RC, Howie AF, Hume R, Matharoo B, Bell J, Hiley C, Jones P, Beckett GJ. The development expression of alpha-, mu- and pi-class glutathione S-transferases in human liver. *Biochimica et Biophysica Acta*. 1989; 993: 186-90.
  39. Diestelhorst C, Boos J, McCune JS, Russell J, Kangaroo SB, Hempel G. Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults. *Cancer Chemotherapy and Pharmacology*. 2013; 72: 991-1000. doi: 10.1007/s00280-013-2275-x.
  40. Diestelhorst C, Boos J, McCune JS, Russell J, Kangaroo SB, Hempel G. Predictive performance of a physiologically based pharmacokinetic model of busulfan in children. *Pediatric Hematology and Oncology*. 2014; 31: 731-42. doi: 10.3109/08880018.2014.927945.
  41. Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. *Pharmacogenetics and Genomics*. 2008; 18: 515-23. doi: 10.1097/FPC.0b013e3282fc9766.
  42. Wang HN, Zhu XY, Zhu Y, Xie QH, Lai LY, Zhao M, Chen YC, Xue J, Hao CM, Gu Y, Lin SY. The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients. *Clinical Immunology*. 2015; 160: 342-8. doi: 10.1016/j.clim.2015.07.010.
  43. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. *Oncogene*. 2003; 22: 7369-75. doi: 10.1038/sj.onc.1206940.
  44. Martinez-Bravo MJ, Calderon-Cabrera C, Marquez-Malaver FJ, Rodriguez N, Guijarro M, Espigado I, Nunez-Roldan A, Perez-Simon JA, Aguilera I. Mismatch on glutathione S-transferase T1 increases the risk of graft-versus-host disease and mortality after allogeneic stem cell transplantation. *Biology of Blood and Marrow Transplantation*. 2014; 20: 1356- 62. doi: 10.1016/j.bbmt.2014.05.008.
  45. Conklin DJ, Haberzettl P, Lesgards JF, Prough RA, Srivastava S, Bhatnagar A. Increased sensitivity of glutathione S-transferase P-null mice to cyclophosphamide-induced urinary bladder toxicity. *Journal of Pharmacology and Experimental Therapeutics*. 2009; 331: 456-69. doi: 10.1124/jpet.109.156513.
  46. Zhong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. *Carcinogenesis*. 1993; 14: 1821-4.
  47. Gray RJ. A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk. *The Annals of Statistics*. 1988; 16: 1141-54.
  48. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics*. 2005; 21: 263-5. doi: 10.1093/

bioinformatics/bth457.

49. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. *The American Journal of Human Genetics*. 2001; 68: 978-89. doi: 10.1086/319501.
50. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. *Bone*

*Marrow Transplantation*. 2013; 48: 452-8. doi: 10.1038/bmt.2012.244.